EIT Health Programme ‘Start-ups Meet Pharma’ – First Module to Start Today at EIT Health Germany in Heidelberg, Germany

They were chosen out of around 100 healthcare start-ups that applied for this year’s premiere of the EIT Health ‘Start-ups Meet Pharma’ programme : 14 start-ups from all over Europe that will tackle five different challenges set up by EIT Health Partners Amgen, Bayer, Ferrer, Janssen and UCB.

These are the participants of ‘Start-ups Meet Pharma 2019’.

The programme that will start with its first of overall four modules from 11th to 14th June at Marsilius Arkaden straight at the Research & Education Office of EIT Health Germany in Heidelberg, Germany wants its participating start-ups to find new medical approaches and solutions for these five challenges:

  1. Providing the right diagnosis at the right point in time– Rheumatoid Arthritis (Partners: Amgen Tech Hub; Amgen Amgevita Brand).
  2. Telemedicine based patient support program in Women’s Health, Cardiology, Oncology, Hematology, Ophthalmology, Pulmonology(Partner: Bayer AG)
  3. Parkinson’s Disease – How to improve the management of “wearing-off” motor episodes(dyskinesias, dystonias); including freezing episodes (Partner: Ferrer)
  4. Creating a Biomarker Measurement Platform: Disease agnostic but focusing on Disease Prevention and Interception with positive and negative prediction models(Partners: Johnson & Johnson World Without Disease).
  5. The measurement of skin health in the assessment of treatment efficacy and ability to predict flares for conditions such as atopic dermatitis and chronic spontaneous urticaria currently relies on direct clinical observation which can be subject to variability and subjectivity (Partners: UCB, Immunology Patient Value Units and Translational Medicine Departments).

Each module will provide the participants with lectures given by experts in the respective challenge topic of the programme’s Pharma partners and allow them to develop their business concepts to the next level. Another essential part of this year’s programme will be a roadshow visiting the Pharma partners during the third module from 8th until 17th of July. The participating start-ups will have the opportunity to get valuable insights on the spot and meet relevant stakeholders from the Pharma partners.

The programme finalizes with a big Pitch Event, the SMP Demo Day, on 26th of July at EIT Health Germany in Heidelberg, Germany, which gives the participants the opportunity to meet potential mentors, relevant EIT Health partners and potential new business partners. During the event the 14 start-ups that are part of the programme will pitch in front of a jury of investors and selected stakeholders of the EIT Health Community. The winner will get the chance to join the EIT Health Summit in December 2019 in Paris.

To register for this unique event please follow this link.

We now invite you to meet the 14 participants of this year’s EIT Health ‘Start-ups Meet Pharma’ here at a glance…

NOVA
Nova is a WhatsApp-like chatbot and has been developed to empower families and individuals suffering from atopic dermatitis. Nova’s aim is to help them lead better lives by integrating them into the treatment process through daily conversations and AI-based recommendations. This way, Nova not only helps to find the highly personal treatment-plan much faster with which the patient is able to keep the atopic dermatitis in check – it also helps doctors and insurers save a significant amount of time and money respectively. Nova intends to save a lot of time by enabling affected and their relatives to (a) self-educate through a highly personalized curriculum provided by subject matter experts, (b) learn about certain flare-up triggers themselves through smart tracking & analytics and also by being able to (c) change certain habits (e.g. better medication adherence) through a gamification approach including nudges and challenges. www.health-companion.com

Pilloxa
Pilloxa is a swedish digital health company based in Stockholm that has developed a patient centric adherence platform to solve the underlying factors to why patients do not take your medication as prescribed. In 2015 Pilloxa did hundreds of interviews with patients, relatives and HCPs to understand the underlying factors to poor adherence. 50 % of the patients do not take their medication as prescribed, 60 % of the patients can not repeat the instructions that their HCP gave them at their last visit. This leads to that around 10 % of all hospitalizations in Sweden are due to poor adherence to medication. Pilloxa’s first product is a smart pillbox with embedded sensors that is connected to a smartphone application. Functionalities onwards include getting reminded only when the patient has forgotten, ability to note how you feel, potential side effects and based on this data Pilloxa can give tailored interventions in the app such as self-education and recommendation to book an online appointment. www.pilloxa.com

Portabiles Healthcare Technologies
In Parkinson’s disease, reduced ability to walk is the most restricting symptom, concerning worldwide 7 million patients. More than 60% of Parkinson’s patients suffer from cyclic changes – switching from inability to move to uncontrollable movements. These motor fluctuations are complex to treat, resulting in frequent hospitalization when poorly cared for and causing direct costs of 6 billion € in industrial nations with 2.5 million Parkinson’s patients. Portabiles Health Care Technologies developed Mobile GaitLab, a medical gait analysis for better diagnosis and therapy of Parkinson’s patients. Mobile GaitLab consists of sensors integrated into orthopedic shoes, meant to be continuously worn by patients at home, combined with a specially developed app for self-assessment. It is used within a personalized care concept for clinical decision support. Physician and supporting Tele-Nurse receive a daily report about timing and severity of the motor fluctuations and the self-assessment. System and algorithms are validated by more than 2.000 clinically stratified gait analyses. www.portabiles-hct.de

aiOmics
aiOMICS is an  AI platform implementing  the following vision: Omics data are Big Data in terms of the number of  molecular  inputs and the  diagnostic, prognostic and response to treatment are Data Science problems, mainly classifications (e.g., diagnostic, prognostics, etc.) or regressions (e.g., survival, relapse, etc.). Thus, the platform is not only disease agnostic, but also  groups many medical problems in one of the two classes. aiOmics uses an innovative approach for various omics data  integration, which does not aggravate the disproportion between the number of inputs and cases. The AI platform was used to develop the best non-invasive multi-cancer diagnostic and early detection test (99% accuracy  for 11 type of cancers) now. (no website)

Zendra Health
Zendra Health is a Dublin-based Digital Health company whose aim is to improve people’s lives and accelerate research into chronic conditions through technology. Zendra Health have used their vast experience in building Digital Health solutions for world-renowned healthcare institutions to develop a platform that provides building blocks to enable healthcare professionals to build evidence-based Digital Health solutions at an 80% reduction in both cost and time-to-market. www.zendrahealth.com

Synosesis Therapeutics
SyNoesis Therapeutics is a biotech start-up with the vision to cure Parkinson’s disease (PD) and other major brain diseases. The start-up aims to capitalize on the potential of a new therapeutic it patented for PD to be further developed to be successful in clinical trials and become the first drug to cure it. The therapeutic has a pleiotropic both disease-modifying and symptomatic effect. It covers remarkably the major unmet needs of PD in several mouse models and has drug-like properties. SyNoesis has achieved several lines of validation so far, the most important of which is the 1st Prize at the EIT HEALTH Catapult for 2018 and the Seal of Excellence for the H2020 SME Instrument. www.synoesistherapeutics.com

Qapsula
Qapsula increases patients’ compliance with therapy and adherence to treatment. The start-up provides an interactive personal assistant, which helps people manage their health more effectively by providing them with personal medical recommendations, monitoring health status, involving patients in the treatment process and connecting them with doctors and coaches. The system consists of various functional blocks that can be combined in different ways, depending on the disease or use case, that help increase the effectiveness of prevention and treatment. www.qapsula.com

DB Health (Reverse Biotechnologies)
DB Health develops a biomarker platform to offer help to medical staff in managing the diagnostic tools to follow a faster and more precise diagnostic pathway. The start-up intends to facilitate the patient’s path to get a safe diagnosis, by guiding the patient in finding facilities that perform biomarker validations analysis. The reduced update possibilities for medical personnel with the last scientific advances can cause long term diagnostic process or worse, incorrect diagnostic, giving wrong therapies with negative health impact and inefficiency. The platform is associated to a database that incorporates biomarkers related to geriatric diseases with info regarding type of disease, disease stage, symptoms, type of the analysis and data on laboratory performing the analysis. An algorithm associated with it and easy to use interface will offer the possibility to medical personnel to efficiency navigate and to choose the best diagnose pathway. http://reverse-senescence-biotechnologies.com

OHDA
OHDA aims to become a medical service integrator and build a patient centered, transaction based telemedicine service platform for all diagnostic needs and stakeholders of healthcare delivery networks. However, such technical capacity is gender, modality as well as case neutral, within the current project special focus was laid on women’s diagnostic and treatment patterns. While women’s health is an adequately addressed concept within applied medical sciences, when it comes to actual diagnosis and treatment, it is lacking the desired patient centered work flow management and the dedicated technical infrastructure. Sourcing women with the right amount of timely information on their own health status can build confidence and trust in upcoming and inevitable treatment. Such state of awareness also brings beneficial and improved psychological conditions helping them easier cope with their illness. http://ohda.com/

Bio2Skin (BestHealth4U)
BestHealth4U is developing and bringing to the market a new generation of medical-grade adhesives. Bio2Skin is a revolutionary nano-based adhesive for medical applications and can be integrated into a wide range of medical devices. It is based on a patented-pending technology that avoids skin injury in prolonged use or upon removal. It is ideal for general use and can provide effective protection against Medical Adhesive-Related Skin Injury (MARSI) in long-term applications such as ostomy, elderly and neo-natal patients. http://besthealth4u.pt/

CalmSkin (Dermus Kft)
Inflammatory skin disorders are a source of distress to around a fifth of the population in the world, many of them children. Flareups can occur without warning and there is a lack of objective evaluation of disease severity (the widely used SCORAD system is based on subjective patient scores). The development of decentralized trials of new medicines would require a cost-effective, portable and objective scoring system. Furthermore, once the medicine is developed, digital health solutions are needed to predict flares and guide optimal treatment for best patient outcome. CalmSkin develops a portable ultrasound device that sees under the surface of the skin. www.dermusvision.com

GP4Research
GP4research is a patient-centered company that develops a Primary Care Practice-Based Research Network (GP4R PBRN) to improve patient access to clinical trials. Embedding Clinical Trials into primary care supported with telemedicine, we bring trials directly to patients. We focus on patients’ comfort by conducting studies in familiar environment close to their home and primary care physician (GP). GP4R PBRN plans to involve in research activities 300 -500 GP practices in Central Eastern Europe with access to 5 M people leaving outside academic centers. Clinical trials will be executed through GPs and nurses supported with telemedicine solutions. Network will operate dedicated software supporting recruitment, process management and data monitoring. The start-up intends to facilitate GP practices with standardized telemedicine kiosks allowing external investigators to conduct remote visits without patient travelling to research site. By expanding geographical reach of traditional research site we provide access to new pool of patients. www.gp4research.com

e-Fasli
This is the only fine-controlled thermotherapeutic device. It can keep the temperature of the skin and the sick bodypart between 25 and 45 C for hours. Wearable and comfortable (various sizes and shapes for peripherals). Using Wi-Fi network and server-side big data analysis it personalizes the therapy. For new users suggest a near-to-optimal treatment basing on data of similar previous patients. It learns the specificity of the user, builds strategies for each symptoms. It can distinct between the short-term (symptomatic) and the long-term (therapeutic) effects. The best treatment for you is never the usual, and it’s hard to find it alone. https://e-fasli.hu

InSignals (Neurotech)
InSignals Neurotech is developing medical devices to support an objective evaluation of motor symptoms of neurological diseases, such as Parkinson’s Disease (PD). The company is a spin-off startup from INESC TEC, a R&D institute in Portugal, aiming to explore the technologies developed in the last years by the Biomedical Research And Innovation (BRAIN) group, whose work has attracted the initial interest of hospitals and players in the healthcare industry. In PD, the quantification of motor signs is fundamental. iHandU consists of a non-invasive wearable hand device that is ergonomically suited in the patient’s hand to evaluate wrist rigidity effectively. Our machine learning algorithms process data related to rigidity and dynamic tremor providing the physicians with real-time information. iHandU has been clinically tested in more than 70 PD patients submitted to DBS surgery at the S. João University Hospital, Porto, Portugal, showing >84% accuracy . New clinical trials are currently being establish in the UK, Germany and the Netherlands to complement the data pack of the benefits in PD, and also other neurological diseases. www.insignals-neurotech.com

Back to top
Image of

Close